Impact of Antiviral Treatment on HBV Mother-to-Child Transmission in 4,157 Pregnant Women

A retrospective real-world study analyzing 4,157 pregnant women with chronic hepatitis B virus (HBV) infection and 4,192 infants to explore factors influencing mother-to-child transmission (MTCT) in cases with extremely high HBV DNA loads (≥ 1×10⁷ IU/ml). The dataset, authored by Wei Yi and last updated in April 2026, contains clinical records where pregnant women received antiviral therapy in the second or third trimester, and infants were followed up after 7 months.

Use Cases

• Modeling the risk of mother-to-child HBV transmission based on maternal HBV DNA load levels.
• Evaluating the efficacy of antiviral treatment timing on transmission outcomes.
• Comparing transmission rates between antiviral therapy and non-therapy groups in a high-risk population.

Strengths

• Includes data from 4,157 pregnant women and 4,192 infants, providing a substantial sample size.
• Focuses on a clinically significant high-risk group (HBV DNA ≥ 1×10⁷ IU/ml).
• Contains real-world outcomes with follow-up data on infant HBV status after 7 months.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for specific analytical methods.
• The retrospective study design may reflect inherent selection or reporting biases.

Provenance

Source

figshare

Collection Method

Retrospective real-world study analyzing clinical records.

Time Range

The study period is not specified in the provided description.

Freshness

Last updated 2026-04-20 05:40:02; freshness should be verified.

Geography

The geographic scope is not specified in the provided description.